**Question:** Indications for use of cyclophosphamide in SLE is

A. Lupus nephritis
B. Raynaud's phenomenon
C. Cutaneous manifestations
D. Oral ulcers

**Core Concept:** Cyclophosphamide is an immunosuppressive drug used in the treatment of systemic lupus erythematosus (SLE). It works by reducing immune system activity, thereby decreasing inflammation and tissue damage. Cyclophosphamide has been traditionally used in severe cases of SLE, especially those with life-threatening organ involvement.

**Why the Correct Answer is Right:** Cyclophosphamide is indicated in SLE patients with severe or life-threatening manifestations, such as:

A. Lupus nephritis: Cyclophosphamide, in combination with corticosteroids, is a cornerstone treatment for severe lupus nephritis. It helps to reduce proteinuria, haematuria, and hypertension, thereby improving renal function and preventing end-stage renal disease.

B. Raynaud's phenomenon: While cyclophosphamide is not specifically indicated for Raynaud's phenomenon, it can be used in severe cases where other treatments, such as corticosteroids, have failed or are not tolerated.

C. Cutaneous manifestations: Cyclophosphamide can be used in severe cutaneous manifestations of SLE to reduce inflammation and prevent organ damage. However, other treatments like corticosteroids and photopheresis might be considered as first-line options.

D. Oral ulcers: Cyclophosphamide is not typically used for oral ulcers in SLE, as corticosteroids and other immunosuppressive agents are usually preferred initial treatments.

**Why Each Wrong Option is Incorrect:**

B. Raynaud's phenomenon: Although cyclophosphamide can be used for severe cases, other treatments like corticosteroids are typically preferred first-line options.

C. Cutaneous manifestations: As mentioned, cyclophosphamide is considered for severe cases, but corticosteroids and photopheresis are often preferred first-line treatments.

D. Oral ulcers: Corticosteroids and other immunosuppressive agents are the initial treatments for oral ulcers associated with SLE. Cyclophosphamide is not the first-choice medication for this manifestation.

**Clinical Pearls:**

1. In severe cases of SLE, a multi-agent immunosuppressive therapy including cyclophosphamide may be considered. However, the choice of medication depends on the specific manifestation and its severity, as well as the patient's overall condition and potential side effects.
2. A well-informed decision should be made after considering the patient's clinical presentation, organ involvement, and potential risks of treatment.
3. In most cases, corticosteroids or other immunosuppressive agents are preferred first-line treatments for oral ulcers and other non-life-threatening manifestations.

**Clinical Scenarios:**

1. For severe lupus nephritis: Cyclophosphamide, in combination with corticosteroids, can be used to improve kidney function